Overview

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

Status:
Completed
Trial end date:
2019-05-07
Target enrollment:
Participant gender:
Summary
The investigators are doing this study to find out if tucatinib is safe for patients with liver problems. This study will look at participants with mild, moderate, and severe liver problems. For each participant with liver problems who takes part, a matching healthy participant who is of similar age, similar body mass index (BMI), and of the same sex will also take part. The study will look at how the drug affects healthy participants compared to participants with liver problems.
Phase:
Phase 1
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.
Treatments:
Tucatinib